OKYO
OKYO Pharma Ltd ADR
NASDAQ: OKYO · HEALTHCARE · BIOTECHNOLOGY
$1.56
+2.63% today
Updated 2026-04-30
Market cap
$82.92M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.11
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
OKYO Pharma Ltd ADR (OKYO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-513950.00 | $-226351.00 | $-878607.00 | $-1.31M | $-4.67M | $-3.82M | $-3.45M | $-1.42M | $-650884.00 | $-651267.00 | $-1.59M | $-1.99M | $-1.20M | $-1.60M | $-5.47M | $-7.70M | $-9.49M | $-1.81M |
| Capital expenditures | $2.82M | $717734.00 | $0.00 | $0.00 | $3.51M | $7.18M | $10.65M | $2.76M | $406045.00 | $375394.00 | $1014.00 | $1322.00 | $5031.00 | $6943.00 | $1669.00 | $5916.00 | $3.00 | $1208.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $2.39M | $114608.00 | $180845.00 | $155878.00 | $825617.00 | $1.33M | $1.41M | $180277.00 | $99203.00 | $18372.00 | $4236.00 | $50533.00 | $36340.00 | $544387.00 | $1.72M | $1.27M | $1.12M | $734989.00 |
| Free cash flow | $-3.33M | $-944085.00 | $-878607.00 | $-1.31M | $-8.18M | $-11.00M | $-14.10M | $-4.18M | $-1.06M | $-1.03M | $-1.60M | $-1.99M | $-1.21M | $-1.61M | $-5.47M | $-7.70M | $-9.49M | $-1.81M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $40.74M | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |